Where does Aimm Therapeutics B.V. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Aimm Therapeutics B.V. ranks #13,842 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Aimm Therapeutics B.V. hold?

Aimm Therapeutics B.V. holds 21 US utility patents granted between 2015 and 2021, spanning 7 technology areas.

What is Aimm Therapeutics B.V.'s Innovation Score?

Aimm Therapeutics B.V. has an Innovation Score of 32.8 out of 100 (42nd percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Aimm Therapeutics B.V. focus on?

Aimm Therapeutics B.V.'s top technology area is C07K (Peptides) with 20 patents, ranking #490 of 3,615 assignees active in that subclass. Grants appear in 7 CPC subclasses total.

Is Aimm Therapeutics B.V.'s patent grant rate increasing or decreasing?

Aimm Therapeutics B.V.'s recent grant velocity is -69% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Aimm Therapeutics B.V.'s patents?

Aimm Therapeutics B.V.'s patents average 21.3 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Aimm Therapeutics B.V. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Aimm Therapeutics B.V.

USPTO PatentsView assignee record - 21 granted patents across 7 technology areas, recorded in grant years 2015–2021. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07K (Peptides).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Aimm ranks #13,842 of 49,997 tracked US assignees by granted-patent volume, with 21 patents across 7 technology areas.

#13,842
of 49,997 US assignees by volume: 42nd percentile
by Innovation Score (32.8/100): 21.3
avg claims per patent: -69%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R13842 · Foreign Corporation #13,842 · 21 grants

GRANTS-SMALL · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-DENSE · TYPE-FRNCORP · VEL-DROP · BOOK-FULL

GRANTS-SMALL 21 grants
MID-PACK #13,842/49,997
PHOTO-FINISH Aerojet Rocketdyne…
CPC-NARROW C07K · 7 areas
INNOV-THIN 32.8/100
CLAIMS-DENSE 21.3 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-DROP -69% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Aerojet Rocketdyne OF DE, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Aimm’s 32.8 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 10.7 pts (33%) Velocity 0.0 pts (0%) Breadth 9.4 pts (29%) Claim depth 12.8 pts (39%)

Qualcomm Incorporated · highest

85
Aimm Therapeutics B V · this assignee

33
3D Lighting… · lowest

7

What this shows Aimm's Innovation Score is 32.8/100 (42nd percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Aimm?

Each dot is one of Aimm’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Aimm’s own 21.3 claims/patent is ABOVE the 11.0 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Aimm vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Aimm's grants concentrate

Aimm Therapeutics B.V. is a focused PatentsView assignee: 7 CPC subclasses with 95.2% of grants classified under C07K (Peptides). Peak complete grant year is 2016 (4 grants) versus a trough of 1 in 2019. By volume, Aimm sits between Aerojet Rocketdyne OF DE, Inc. and American AIR Filter Company, Inc..

Aerojet Rocketdyn…

21
Agari Data

21
Agricultural Tech…

21
AHT Cooling Syste…

21
Alere Switzerland

21
Alstom Holdings

21
Ambilight

21
American AIR Filt…

21
Aimm Therapeutics… ◀

21

What this shows Aimm holds 21 patents at rank #13,836, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Aimm

By rank, the assignees closest to #13,836 in granted patent volume.

Leaders in C07K (Peptides)

Other assignees with the most granted patents in Aimm's primary technology class.

Aimm's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

33 42nd percentile higher than 42% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2021

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Aimm Therapeutics B.V. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	3	14.3%
2016	4	19.0%
2017	4	19.0%
2018	4	19.0%
2019	1	4.8%
2020	4	19.0%
2021	1	4.8%

Which technologies does Aimm Therapeutics B.V. patent most?

C07K - Peptides 20

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 11

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 11

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 6

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 5

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 1

C12P - Fermentation OR Enzyme-using Processes TO Synthesise A Desired Chemical Compound OR Composition OR TO Separate Optical Isomers From A Racemic Mixture 1

Top 7 of 7 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Aimm Therapeutics B.V.'s patent record in context - here's where to go next.

Aimm Therapeutics B.V.'s lead technology class is C07K (Peptides), 95.2% of its portfolio - see every assignee active in that class. Explore C07K
Ranked #13,842 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Aimm Therapeutics B.V. against Aerojet Rocketdyne OF DE, Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 32.8/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.